Syndax Pharmaceuticals, Inc.
SNDX Healthcare Biotechnology
Syndax Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $172.4 million, up 627.8% from fiscal 2024. In the quarter to June 2026, revenue grew 91.8%, EPS grew 33.7%, free cash flow grew 65.5% and total debt rose 71.0%, each against the same quarter a year earlier.
Follow SNDX
Syndax Pharmaceuticals, Inc. (SNDX) EV/Sales
As of 16 October 2026, Syndax Pharmaceuticals, Inc. (SNDX) trades at a EV/Sales of 4.8×. Over the past ten years it has ranged from −84.0× (June 2016) to 689× (April 2021); the current reading is higher than 9% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.3× | 73.17% |
| FY2024 | 5.9× | 16.41% |
| FY2021 | 5.1× | (98.80%) |
| FY2020 | 426× | 209.17% |
| FY2019 | 138× | 356.33% |
| FY2018 | 30.2× | (6.39%) |
| FY2017 | 32.2× | 155.18% |
| FY2016 | 12.6× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.9× | (16.54%) |
| Mar 2026 | 9.5× | (7.47%) |
| Dec 2025 | 10.3× | (6.15%) |
| Sep 2025 | 11.0× | 25.27% |
| 32 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LBRX LB Pharmaceuticals Inc compare | n/m |
| GHRS GH Research PLC compare | n/m |
| DMRA Galecto, Inc. compare | n/m |
| VOR Vor Biopharma Inc. compare | n/m |
| BCAX Bicara Therapeutics Inc. compare | n/m |
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| SNDX Syndax Pharmaceuticals, Inc. | 4.8× |
| NKTR Nektar Therapeutics compare | 18.3× |
| TSHA Taysha Gene Therapies, Inc. compare | 78.8× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)